► See the article "Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer" in volume 27, e15.
histopathological (FIGO stage II) parameters were significant by univariate analysis but not significant in the multivariate analysis. However, because IFH was highly correlated with primary tumor size, depth of cervical invasion, SUV tumor , MTV tumor , and TLG tumor , the problem of multicollinearity will cause the regression model unstable [7] .
Many techniques have been used to characterize tumor heterogeneity on PET including visual evaluation, CV of SUV, area under the curve of the cumulative histogram, and fractal or textural feature analysis [8] . A study analyzed 555 pretreatment 18 F-FDG PET images of cancer patients (45 cervix, 101 lung [non-small cell], 139 head and neck, 112 esophagus, and 158 breast) using four robust texture feature parameters. The relationships between metabolically active tumor volume and texture features were similar across the different tumor types. Stage, volume, and heterogeneity were independent prognostic factors for non-small cell lung cancer for instance [8] .
The texture analysis involved multiple approaches, such as histogram-based methods. The heterogeneity descriptors (HDs) disregard the inherent spatial relationship between voxel values, and reflect the voxel-value frequency distribution using first-order statistics [3] . Other approaches account for the spatial arrangement of the voxel values within the tumor using second-order gray level co-occurrence matrix or higher-order statistics, such as graylevel run length matrix, gray-level size zone matrix, or neighboring gray-level dependence matrix, to represent the spatial arrangement of intensities in a 3D volume of interest [3, 5] . However, same descriptor name may be used for descriptors calculated from different definitions resulting in confusions, therefore, a plea to standardize the HDs is called [3] . Despite significant results are noted by applying numerous parameters that characterized PET heterogeneity, the biological correlation demands further investigation.
In conclusion, measuring tumor metabolic heterogeneity on PET data is potentially useful for clinical oncology practice. Type I error is unavoidable in studies investigating many HDs in a limited set of patients and outcome events. Further prospective, large-scale studies have to be performed with the well-defined HDs to validate their true utility in the management of cervical cancer.
